Initially, the approval was for BRAF V600E mutations for only a few cancers such as melanoma, non-small cell lung cancer, and anaplastic thyroid cancer but evidence of added efficacy in other cancers led to pan-tumor approval. Here, BRAF is linked to neoplasm.